Yang Seokhun, Hu Xinyang, Zhang Jinlong, Jiang Jun, Hahn Joo-Yong, Doh Joon-Hyung, Lee Bong-Ki, Kim Weon, Huang Jinyu, Jiang Fan, Zhou Hao, Chen Peng, Tang Lijiang, Jiang Wenbing, Chen Hao, Chen Xiaomin, He Wenming, Ahn Sung Gyun, Tahk Seung-Jea, Kim Ung, Hwang Doyeon, Kang Jeehoon, Ki You-Jeong, Shin Eun-Seok, Nam Chang-Wook, Wang Jian'an, Koo Bon-Kwon
Seoul National University Hospital, Seoul, Republic of Korea.
The Second Affiliated Hospital of Zhejiang University School of Medicine, State Key Laboratory of Transvascular Implantation Devices, Heart Regeneration and Repair Key Laboratory of Zhejiang Province, Transvascular Implantation Devices Research Institute, Hangzhou, Hangzhou, China.
J Am Coll Cardiol. 2025 Aug 26;86(8):593-606. doi: 10.1016/j.jacc.2025.06.042.
The optimal treatment strategy for patients with intermediate coronary stenosis remains uncertain.
The aim of this study was to investigate the long-term outcomes of a randomized, open-label, multinational trial comparing fractional flow reserve (FFR)-guided vs intravascular ultrasound (IVUS)-guided treatment strategies.
Patients aged ≥19 years with de novo intermediate coronary stenosis (40%-70%) and target vessel diameters ≥2.5 mm were randomized 1:1 to FFR- or IVUS-guided treatment across 18 sites in Korea and China. The primary endpoint was a composite of all-cause death, myocardial infarction, and any revascularization occurring after the index procedure. Secondary endpoints included individual components of the primary outcome and per vessel outcomes according to treatment type. Extended follow-up continued through September 2024.
Between July 2016 and August 2019, 1,682 patients were assigned to the FFR-guided (n = 838) and IVUS-guided (n = 844) groups. Over a median follow-up period of 6.3 years (Q1-Q3: 5.6-6.9 years), the primary outcome occurred in 339 patients (22.0%), with no statistically significant difference between groups (179 [23.1%] for FFR vs 160 [20.9%] for IVUS; HR: 1.15; 95% CI: 0.93-1.42; P = 0.208). The revascularization rate after the index procedure was higher in the FFR group (113 [14.9%] vs 87 [11.8%]; HR: 1.32; 95% CI: 1.00-1.75; P = 0.049), particularly for target vessel revascularization (72 [9.6%] vs 44 [6.2%]; HR: 1.67; 95% CI: 1.15-2.43; P = 0.007). Landmark analysis at 2 years and per vessel analyses indicated that the higher revascularization rate after the index procedure was driven primarily by late (2-7 years) revascularizations in vessels in which percutaneous coronary intervention (PCI) was initially deferred. Nevertheless, the overall rate of target vessel PCI, including procedures at index and during follow-up, was significantly lower in the FFR group (38.8% vs 60.5%; P < 0.001), with no statistically significant differences in the annual cumulative incidence of death or myocardial infarction between groups.
FFR-guided and IVUS-guided treatment strategies resulted in comparable long-term outcomes, with no significant difference in patient-oriented composite outcomes. Although FFR-guided treatment was associated with a higher incidence of late target vessel revascularization, the overall target vessel PCI rate, accounting for both the index procedure and revascularization during follow-up, remained significantly lower in the FFR-guided treatment group, with comparable rates of hard outcomes between the 2 groups.
中度冠状动脉狭窄患者的最佳治疗策略仍不确定。
本研究旨在调查一项随机、开放标签、多国试验的长期结果,该试验比较了血流储备分数(FFR)引导与血管内超声(IVUS)引导的治疗策略。
年龄≥19岁、新发中度冠状动脉狭窄(40%-70%)且靶血管直径≥2.5 mm的患者按1:1随机分配至FFR引导或IVUS引导治疗组,在韩国和中国的18个地点进行。主要终点是首次手术后发生的全因死亡、心肌梗死和任何血运重建的复合终点。次要终点包括主要结局的各个组成部分以及根据治疗类型的每支血管结局。延长随访持续至2024年9月。
2016年7月至2019年8月期间,1682例患者被分配至FFR引导组(n = 838)和IVUS引导组(n = 844)。在中位随访期6.3年(第一四分位数-第三四分位数:5.6-6.9年)内,339例患者(22.0%)出现主要结局,两组之间无统计学显著差异(FFR组为179例[23.1%],IVUS组为160例[20.9%];风险比:1.15;95%置信区间:0.93-1.42;P = 0.208)。FFR组首次手术后的血运重建率更高(113例[14.9%]对87例[11.8%];风险比:1.32;95%置信区间:1.00-1.75;P = 0.049),特别是靶血管血运重建(72例[9.6%]对44例[6.2%];风险比:1.67;95%置信区间:1.15-2.43;P = 0.007)。2年时的标志性分析和每支血管分析表明,首次手术后较高的血运重建率主要由最初推迟经皮冠状动脉介入治疗(PCI)的血管中的晚期(2-7年)血运重建驱动。然而,FFR组包括首次手术和随访期间手术在内的靶血管PCI总体率显著更低(38.8%对60.5%;P < 0.001),两组之间死亡或心肌梗死的年度累积发生率无统计学显著差异。
FFR引导和IVUS引导的治疗策略产生了相当的长期结果,在以患者为导向的复合结局方面无显著差异。尽管FFR引导治疗与晚期靶血管血运重建发生率较高相关,但FFR引导治疗组包括首次手术和随访期间血运重建在内的总体靶血管PCI率仍显著更低,两组之间严重结局发生率相当。